Published in Clin Chem on November 12, 2009
Mass-spectrometry-based clinical proteomics--a review and prospective. Analyst (2010) 1.06
Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics. ScientificWorldJournal (2014) 0.85
Transcriptomic and Proteomic Investigation of HSP90A as a Potential Biomarker for HCC. Med Sci Monit (2015) 0.75
The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics (2002) 16.08
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem (2008) 3.23
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2009) 2.42
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem (2006) 1.95
Proteomics: a new diagnostic frontier. Clin Chem (2006) 1.82
The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer (2006) 1.79
Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin Chem (2008) 1.66
Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem (2005) 1.16
Full-length characterization of proteins in human populations. Clin Chem (2009) 1.01
Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin Chem (2010) 0.95
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
A mitochondrial protein compendium elucidates complex I disease biology. Cell (2008) 13.51
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6.96
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet (2006) 4.67
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics (2009) 3.65
Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest (2011) 3.23
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A (2009) 2.94
A human proteome detection and quantitation project. Mol Cell Proteomics (2009) 2.80
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J (2007) 2.48
Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest (2008) 2.46
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol (2011) 2.44
The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics (2011) 2.43
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2009) 2.42
The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics (2003) 2.41
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
EMRE is an essential component of the mitochondrial calcium uniporter complex. Science (2013) 2.39
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell (2013) 2.35
Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol (2009) 2.27
Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods (2013) 2.22
Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin Chem (2009) 2.14
Phosphorylation by cyclin B-Cdk underlies release of mitotic exit activator Cdc14 from the nucleolus. Science (2004) 2.14
Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol Cell Proteomics (2008) 2.11
Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics (2009) 2.09
Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods (2013) 2.04
Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics (2003) 2.04
Metabolic signatures of exercise in human plasma. Sci Transl Med (2010) 1.99
A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol (2010) 1.90
PEPPeR, a platform for experimental proteomic pattern recognition. Mol Cell Proteomics (2006) 1.90
Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. Anal Chem (2010) 1.86
Systematic discovery of TLR signaling components delineates viral-sensing circuits. Cell (2011) 1.83
Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem (2009) 1.81
DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell (2010) 1.78
Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics (2011) 1.71
Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin Chem (2008) 1.66
High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem (2008) 1.62
ZBED6, a novel transcription factor derived from a domesticated DNA transposon regulates IGF2 expression and muscle growth. PLoS Biol (2009) 1.61
A reagent resource to identify proteins and peptides of interest for the cancer community: a workshop report. Mol Cell Proteomics (2006) 1.60
Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol Cell Proteomics (2012) 1.58
Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics (2011) 1.52
Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics (2012) 1.48
Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics (2011) 1.44
Panorama: a targeted proteomics knowledge base. J Proteome Res (2014) 1.43
Large-scale identification of ubiquitination sites by mass spectrometry. Nat Protoc (2013) 1.41
H2A.Z landscapes and dual modifications in pluripotent and multipotent stem cells underlie complex genome regulatory functions. Genome Biol (2012) 1.33
Place of pattern in proteomic biomarker discovery. J Proteome Res (2005) 1.32
TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin. Oncogene (2004) 1.30
Quantitative assessment of chromatin immunoprecipitation grade antibodies directed against histone modifications reveals patterns of co-occurring marks on histone protein molecules. Mol Cell Proteomics (2012) 1.27
Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell (2012) 1.26
Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer (2014) 1.23
Empirical Bayes analysis of quantitative proteomics experiments. PLoS One (2009) 1.21
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov (2013) 1.20
Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res (2013) 1.20
Directed sample interrogation utilizing an accurate mass exclusion-based data-dependent acquisition strategy (AMEx). J Proteome Res (2009) 1.18
Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics. BMC Bioinformatics (2012) 1.18
Anti-peptide antibody screening: selection of high affinity monoclonal reagents by a refined surface plasmon resonance technique. J Immunol Methods (2008) 1.17
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. Elife (2014) 1.16
Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res (2010) 1.15
Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. Cell Metab (2011) 1.14
N-Terminal peptide labeling strategy for incorporation of isotopic tags: a method for the determination of site-specific absolute phosphorylation stoichiometry. Rapid Commun Mass Spectrom (2002) 1.13
Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem (2009) 1.10
Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem (2009) 1.07
National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation (2004) 1.07
Mass-spectrometry-based clinical proteomics--a review and prospective. Analyst (2010) 1.06
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A (2012) 1.06
Integration of proteomic-based tools for improved biomarkers of myocardial injury. Clin Chem (2009) 1.05
High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res (2012) 1.04
Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res (2011) 1.04
Cdk5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway. PLoS One (2011) 1.04
Mass spectrometry-based methods for phosphorylation site mapping of hyperphosphorylated proteins applied to Net1, a regulator of exit from mitosis in yeast. Mol Cell Proteomics (2002) 1.04
Proteomics: from basic research to diagnostic application. A review of requirements & needs. J Proteome Res (2005) 1.03
Identification of regulators of the innate immune response to cytosolic DNA and retroviral infection by an integrative approach. Nat Immunol (2012) 1.02
Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol Cell Proteomics (2014) 1.02
Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS). Mol Cell Proteomics (2013) 1.01
Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. Proc Natl Acad Sci U S A (2011) 1.01
Therapeutic potential of the plasma proteome. Curr Opin Mol Ther (2003) 0.99
An unbiased approach to identify endogenous substrates of "histone" deacetylase 8. ACS Chem Biol (2014) 0.97
MALDI immunoscreening (MiSCREEN): a method for selection of anti-peptide monoclonal antibodies for use in immunoproteomics. J Immunol Methods (2010) 0.94
Mycobacterial Esx-3 requires multiple components for iron acquisition. MBio (2014) 0.93
Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis. Cell Rep (2013) 0.91